Liver Histology Predicts Liver Regeneration and Outcome in ALPPS: Novel Findings from A Multicenter Study.


Journal

Annals of surgery
ISSN: 1528-1140
Titre abrégé: Ann Surg
Pays: United States
ID NLM: 0372354

Informations de publication

Date de publication:
24 Jul 2023
Historique:
pubmed: 24 7 2023
medline: 24 7 2023
entrez: 24 7 2023
Statut: aheadofprint

Résumé

Alterations in liver histology influence the liver´s capacity to regenerate, but the relevance of each of the different changes rapid liver growth induction is unknown. This study aimed to analyze the influence of the degree of histological alterations during the first and second stages on the ability of the liver to regenerate. This cohort study included data obtained from the International ALPPS Registry between November 2011 and October 2020. Only patients with colorectal liver metastases were included in the study. We developed a histological risk score based on histological changes (stages 1 and 2) and a tumor pathology score based on the histological factors associated with poor tumor prognosis. In total, 395 patients were included. The time to reach stage 2 was shorter in patients with a low histological risk stage 1 (13 vs. 17 d, P ˂0.01), low histological risk stage 2 (13 vs. 15 d, P ˂0.01) and low pathological tumor risk (13 vs. 15 d, P ˂0.01). Regarding interval stage, there was a higher inverse correlation in high histological risk stage 1 group compared to low histological risk 1 group in relation with future liver remnant body weight (r=-0.1 and r=-0.08, respectively), and future liver remnant (r=-0.15 and r=-0.06, respectively). ALPPS is associated with increased histological alterations in the liver parenchyma. It seems that the more histological alterations present and the higher the number of poor prognostic factors in the tumor histology, the longer the time to reach the second stage.

Sections du résumé

BACKGROUND AND AIMS OBJECTIVE
Alterations in liver histology influence the liver´s capacity to regenerate, but the relevance of each of the different changes rapid liver growth induction is unknown. This study aimed to analyze the influence of the degree of histological alterations during the first and second stages on the ability of the liver to regenerate.
METHODS METHODS
This cohort study included data obtained from the International ALPPS Registry between November 2011 and October 2020. Only patients with colorectal liver metastases were included in the study. We developed a histological risk score based on histological changes (stages 1 and 2) and a tumor pathology score based on the histological factors associated with poor tumor prognosis.
RESULTS RESULTS
In total, 395 patients were included. The time to reach stage 2 was shorter in patients with a low histological risk stage 1 (13 vs. 17 d, P ˂0.01), low histological risk stage 2 (13 vs. 15 d, P ˂0.01) and low pathological tumor risk (13 vs. 15 d, P ˂0.01). Regarding interval stage, there was a higher inverse correlation in high histological risk stage 1 group compared to low histological risk 1 group in relation with future liver remnant body weight (r=-0.1 and r=-0.08, respectively), and future liver remnant (r=-0.15 and r=-0.06, respectively).
CONCLUSION CONCLUSIONS
ALPPS is associated with increased histological alterations in the liver parenchyma. It seems that the more histological alterations present and the higher the number of poor prognostic factors in the tumor histology, the longer the time to reach the second stage.

Identifiants

pubmed: 37487004
doi: 10.1097/SLA.0000000000006024
pii: 00000658-990000000-00595
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.

Déclaration de conflit d'intérêts

Conflicts of interest: The authors declare no conflicts of interest. No third-party financial funds or materials were accepted or necessary for this research project.

Auteurs

Victor Lopez-Lopez (V)

Department of Surgery and Liver and Pancreas transplantation, Virgen de la Arrixaca Clinic and University Hospital, Murcia, Spain. IMIB.

Michael Linecker (M)

Department of Surgery and Transplantation, University Medical Center Schleswig-Holstein, Campus Kiel, Germany.

Albert Caballero-Llanes (A)

Department of Pathology, Virgen de la Arrixaca Clinic and University Hospital, Murcia, Spain. IMIB.

Tim Reese (T)

Department of Surgery, Division of Liver-, Bileduct- and Pancreatic Surgery, Asklepios Hospital Barmbek, Ruebenkamp 220, 22307, Hamburg, Germany.

Karl J Oldhafer (KJ)

Department of Surgery, Division of Liver-, Bileduct- and Pancreatic Surgery, Asklepios Hospital Barmbek, Ruebenkamp 220, 22307, Hamburg, Germany.

Roberto Hernandez-Alejandro (R)

Department of Surgery, Western University, Ontario, Canada; Division of Transplantation/Hepatobiliary Surgery, Department of Surgery, University of Rochester, NY, USA.

Mauro Tun-Abraham (M)

Department of Surgery, Western University, Ontario, Canada; Division of Transplantation/Hepatobiliary Surgery, Department of Surgery, University of Rochester, NY, USA.

Jun Li (J)

Department of General, Visceral and Thoracic Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Mohammad Fard-Aghaie (M)

Department of General, Visceral and Thoracic Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Henrik Petrowsky (H)

Department of Surgery and Transplantation, Swiss HPB and Transplant Center, University Hospital Zurich, Zurich, Switzerland.

Roberto Brusadin (R)

Department of Surgery and Liver and Pancreas transplantation, Virgen de la Arrixaca Clinic and University Hospital, Murcia, Spain. IMIB.

Asuncion Lopez-Conesa (A)

Department of Surgery and Liver and Pancreas transplantation, Virgen de la Arrixaca Clinic and University Hospital, Murcia, Spain. IMIB.

Francesca Ratti (F)

Hepatobiliary Surgery Division, Department of Surgery, IRCCS San Raffaele Hospital, School of Medicine, Milan, Italy.

Luca Aldrighetti (L)

Hepatobiliary Surgery Division, Department of Surgery, IRCCS San Raffaele Hospital, School of Medicine, Milan, Italy.

Ali Ramouz (A)

Department of General, Visceral and Transplant Surgery, Heidelberg University Hospital, Heidelberg, Germany.

Arianeb Mehrabi (A)

Department of General, Visceral and Transplant Surgery, Heidelberg University Hospital, Heidelberg, Germany.

Marcel Autran Machado (M)

Department of Surgery, Hospital Adventista Silvestre, Rio de Janeiro, RJ, Brazil.

Victoria Ardiles (V)

Department of Surgery, Division of HPB Surgery, Liver Transplant Unit, Italian Hospital Buenos Aires, Argentina.

Eduardo De Santibañes (E)

Department of Surgery, Division of HPB Surgery, Liver Transplant Unit, Italian Hospital Buenos Aires, Argentina.

Arthur Marichez (A)

Centre Hépato-Biliaire, Hôpital Paul Brousse, Villejuif, France.

René Adam (R)

Centre Hépato-Biliaire, Hôpital Paul Brousse, Villejuif, France.

Stéphanie Truant (S)

Department of Digestive Surgery and Transplantation, University Hospital, Lille, France.

Francois-René Pruvot (FR)

Department of Digestive Surgery and Transplantation, University Hospital, Lille, France.

Pim Olthof (P)

Department of Surgery, Amsterdam University Medical Centers, 1105 AZ Amsterdam, The Netherlands.

Thomas Van Gulick (T)

Department of Surgery, Amsterdam University Medical Centers, 1105 AZ Amsterdam, The Netherlands.

Roberto Montalti (R)

Department of Clinical Medicine and Surgery, Federico II University Hospital Naples, 80131 Napoli, Italy.

Roberto I Troisi (RI)

Department of Clinical Medicine and Surgery, Federico II University Hospital Naples, 80131 Napoli, Italy.

Philipp Kron (P)

HPB and Transplant Unit, St. James's University Hospital, Leeds, UK.

Peter Lodge (P)

HPB and Transplant Unit, St. James's University Hospital, Leeds, UK.

Patryk Kambakamba (P)

Department of Hepatobiliary Surgery and Liver Transplantation, St. Vincent's University Hospital, Dublin, Ireland.

Emir Hoti (E)

Department of Hepatobiliary Surgery and Liver Transplantation, St. Vincent's University Hospital, Dublin, Ireland.

Carlos Martinez-Caceres (C)

Investigation Support Platforms, IMIB-Arrixaca, Murcia, Spain.

Jesus de la Peña-Moral (J)

Department of Pathology, Virgen de la Arrixaca Clinic and University Hospital, Murcia, Spain. IMIB.

Pierre-Alain Clavien (PA)

Department of General, Visceral and Thoracic Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Ricardo Robles-Campos (R)

Department of Surgery and Liver and Pancreas transplantation, Virgen de la Arrixaca Clinic and University Hospital, Murcia, Spain. IMIB.

Classifications MeSH